BHP, Rio Tinto shares rise as peer Vale posts smaller-than-feared Q2 profit drop
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently sold shares worth approximately $3.6 million. The transactions took place on December 23, 2024, and involved multiple sales of common stock at prices ranging from $356.174 to $363.95 per share. These sales were part of a pre-arranged trading plan under Rule 10b5-1. The stock has shown remarkable strength, delivering a 64% return year-to-date, while maintaining an excellent financial health score according to InvestingPro analysis.
In addition to the sales, Benkowitz exercised stock options to acquire 10,000 shares at a price of $111.00 per share. Following these transactions, Benkowitz's holdings are managed through a trust, reflecting shared investment and voting power with his spouse. The company maintains impressive gross profit margins of 89% and trades at a modest P/E ratio of 15x.
The transactions highlight the strategic financial activities of United Therapeutics' executive team, as they continue to manage their equity positions in the company. InvestingPro analysis indicates the stock is currently trading near its Fair Value, with 12 additional key insights available to subscribers, including detailed metrics on the company's high shareholder yield and strong financial position.
In other recent news, United Therapeutics Corporation has reported a series of significant developments. The company announced a successful transplantation of a gene-edited pig kidney into a human patient, marking a milestone in xenotransplantation. This was followed by robust third-quarter financial results, with revenues reaching $748.9 million, primarily driven by the strong performance of treprostinil-based products like Tyvaso.
United Therapeutics also completed a $1 billion accelerated share repurchase program. Analyst firms have been active in assessing the company's performance. H.C. Wainwright reaffirmed a Buy rating, citing strategic positioning and proactive measures, and increased the price target to $425. Ladenburg Thalmann, on the other hand, maintained a Neutral rating but raised the price target to $344.
These recent developments indicate United Therapeutics' strategic focus on expanding commercial ventures and research and development. The company is eyeing future clinical milestones, including the TETON 2 study results, and is awaiting a potential FDA decision on its Centralized Lung Evaluation System in 2025. United Therapeutics has also shown a commitment to addressing the shortage of transplantable organs for patients with end-stage organ disease through innovations in xenotransplantation, regenerative medicine, 3D organ bioprinting, and bio-artificial organs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.